Paris – 18 June 2014 – EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs, today congratulated Pixium Vision, specialised in developing systems to restore the vision of patients who have lost their sight, on its listing in Compartment C of Euronext’s regulated market in Paris.
Founded in 2011 by Bernard Gilly, Professor José-Alain Sahel, and a number of scientists from well-known academic and technology institutions, Pixium Vision develops Vision Restoration Systems (VRS) for people who have lost their sight due to degenerative conditions affecting retinal photoreceptors.
The company has developed IRIS®, a system combining several high-tech components with surgery and re-education. Pixium Vision’s VRSs aim to allow people who have lost their sight to live more autonomously. IRIS1 is currently undergoing clinical tests. To date patients are supporting the implants well, and improvements have been observed in the visual perception of blind patients. Pixium Vision is also developing PRIMA, a second VRS, that uses an implant positioned under the retina. PRIMA is currently in the preclinical development stage.
Pixium Vision (ticker code: PIX) was listed through the admission to trading of the 7,964,554 shares making up its equity and the issue of 4,166,666new shares issued in a Global Offering, including full exercise of the extension option and before possible exercise of the over-allotment.
The admission and issue price of Pixium Vision shares was set at €8.28 per share. Market capitalisation was around €100.4million on the day of listing. Altogether the offering raised €34.5million.
“We are delighted to welcome Pixium Vision to EnterNext. Listing will raise the group’s visibility on international markets and give it access to a larger pool of investors, allowing it to develop and successfully market its innovative technology,” said Eric Forest, Chairman and CEO of EnterNext.
Pixium Vision’s Chairman and CEO Bernard Gilly added: “Our successful IPO reflects investor confidence in Pixium Vision’s strategy. We are convinced that Pixium Vision, drawing on our complementary IRIS® and PRIMA technologies, is uniquely positioned to become a world leader in vision restoration systems, helping people who have lost their sight live more autonomously.”